After 3 strikes a CETP inhibitor finally scores BARCELONA — Finally there is a CETP inhibitor that actually confers more benefit than risk: anacetrapib. The benefit emerged from the Randomized EValuation of the Effects of Anacetrapib through Lipid-modification (HPS3/TIMI55-REVEAL) trial which was presented here at the European Society of Cardiology meeting and published simultaneously in the New ...
REVEAL revealed: A slightly positive CETP inhibitor trial
By Larry Husten
6 Sep 2017